drugset

drugset / Trial / NCT05239702

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

NCT05239702 ↗

Phase 0 Unknown 75 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases

Timeline

Start: 2022-02-28
Primary completion: 2024-12-01
Completion: 2024-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD7 CAR-T cells	Cell therapy	—	Intravenous

Indications